Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported ...

NEW YORK and BERLIN, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Perception Neuroscience (Perception), an atai Life Sciences (atai) biopharmaceutical company focused on developing innovative therapies in ...

– Enrollment remains ongoing in a Phase 2 proof-of-concept study of ALTO-101 in patients with CIAS – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (ANRO) a clinical-stage ...

Jefferies analyst Andrew Tsai raised the firm’s price target on Alto Neuroscience (ANRO) to $25 from $15 and keeps a Buy rating on the shares.

Completed enrollment of Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine). Last patient expected to be dosed this week, with the total ...

– ALTO-101 demonstrated a favorable pharmacokinetic and tolerability profile; novel transdermal formulation delivered significantly greater drug exposure and fewer adverse events typically associated ...

– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...

Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Trace Neuroscience, Inc., a biopharmaceutical company expanding the promise of genomic medicine for people living with neurodegenerative diseases, today ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best young stocks with huge upside potential. On October 3, Alto Neuroscience announced that the US FDA granted Fast Track designation to its drug ...